{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:37:35Z","timestamp":1793191055806,"version":"4.5.0"},"reference-count":99,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,4,6]],"date-time":"2011-04-06T00:00:00Z","timestamp":1302048000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:p>\n                    Phosphodiesterase 4 (PDE4) is a member of the PDE enzyme superfamily that inactivates cyclic adenosine monophosphate and cyclic guanosine monophosphate, and is the main PDE isoenzyme occurring in cells involved in inflammatory airway disease such as chronic obstructive pulmonary disease (COPD). COPD is a preventable and treatable disease and is characterized by airflow obstruction that is not fully reversible. Chronic progressive symptoms, particularly dyspnoea, chronic bronchitis and impaired overall health are worse in those who have frequent, acute episodes of symptom exacerbation. Although several experimental PDE4 inhibitors are in clinical development, roflumilast, a highly selective PDE4 inhibitor, is the first in its class to be licensed, and has recently been approved in several countries for oral, once\u2010daily treatment of severe COPD. Clinical trials have demonstrated that roflumilast improves lung function and reduces exacerbation frequency in COPD. Furthermore, its unique mode of action may offer the potential to target the inflammatory processes underlying COPD. Roflumilast is effective when used concomitantly with all forms of bronchodilator and even in patients treated with inhaled corticosteroids. Roflumilast thus represents an important addition to current therapeutic options for COPD patients with chronic bronchitis, including those who remain symptomatic despite treatment. This article reviews the current status of PDE4 inhibitors, focusing on the pharmacokinetics, efficacy and safety of roflumilast. In particular, it provides an overview of the effects of roflumilast on lung function and exacerbations, glucose homoeostasis and weight loss, and the concomitant use of long\u2010acting beta\n                    <jats:sub>2<\/jats:sub>\n                    \u2010adrenergic receptor agonists and short\u2010acting muscarinic receptor antagonists.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>LINKED ARTICLES<\/jats:bold>\n                    This article is part of a themed issue on Respiratory Pharmacology. To view the other articles in this issue visit\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/dx.doi.org\/10.1111\/bph.2011.163.issue-1\">http:\/\/dx.doi.org\/10.1111\/bph.2011.163.issue\u20101<\/jats:ext-link>\n                  <\/jats:p>","DOI":"10.1111\/j.1476-5381.2011.01218.x","type":"journal-article","created":{"date-parts":[[2011,1,14]],"date-time":"2011-01-14T07:27:37Z","timestamp":1294990057000},"page":"53-67","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":230,"title":["Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease"],"prefix":"10.1111","volume":"163","author":[{"given":"Klaus F.","family":"Rabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,4,6]]},"reference":[{"key":"e_1_2_10_2_1","article-title":"Fluoroalkoxy\u2010substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors","author":"Amschler H","year":"1995","journal-title":"PCT Patent"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61375-1"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00063198-200003000-00014"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.08.021"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP44572"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006294529"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008330980"},{"key":"e_1_2_10_9_1","article-title":"No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using Cimetidine","author":"B\u00f6hmer GM","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/15412550701341053"},{"key":"e_1_2_10_11_1","first-page":"121","article-title":"PDE4 inhibitors as potential therapeutic agents in the treatment of COPD\u2010focus on roflumilast","volume":"2","author":"Boswell\u2010Smith V","year":"2007","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.02.045"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706495"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612023394665"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200610-1563OC"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61255-1"},{"issue":"54","key":"e_1_2_10_17_1","first-page":"Abstract P4001","article-title":"Roflumilast in the treatment of COPD: a pooled safety analysis","volume":"36","author":"Calverley PMA","year":"2010","journal-title":"Eur Respir J Suppl"},{"key":"e_1_2_10_18_1","unstructured":"CalverleyPMA FabbriLM RabeKF MosbergH(2010b).Roflumilast in the treatment of COPD: a pooled safety analysis. Presented at theEuropean Respiratory Society Annual Congress Barcelona Spain 18\u201022 September 2010: Poster 4732."},{"key":"e_1_2_10_19_1","first-page":"A2025","article-title":"Cigarette smoke\u2010induced inflammatory and oxidative response in mice and pharmacological intervention studies involving compounds with different mechanism of action","volume":"179","author":"Carnini C","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_10_20_1","first-page":"A12","article-title":"Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease (COPD) concomitantly treated with tiotropium or salmeterol","volume":"19","author":"Chapman KR","year":"2010","journal-title":"Prim Care Respir J"},{"key":"e_1_2_10_21_1","first-page":"A5671","article-title":"Pharmacology Of SCH900182, A Potent, Selective Inhibitor Of PDE4 For Inhaled Administration","volume":"181","author":"Chapman RW","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R200029200"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2008.00041.x"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544010-00002"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.01.246"},{"issue":"38","key":"e_1_2_10_26_1","first-page":"108s","article-title":"Patients with severe renal impairment do not require dose adjustments of roflumilast","volume":"20","author":"Drollmann A","year":"2002","journal-title":"Eur Respir J"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj3210165"},{"key":"e_1_2_10_28_1","first-page":"A5620","article-title":"Treatment of airway mucus hypersecretion and postnasal drip syndrome by the PDF4 inhibitor ibudilast in patients with chronic airway inflamation","volume":"181","author":"Etsuko T","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61252-6"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.17.5.811"},{"key":"e_1_2_10_31_1","first-page":"A905","article-title":"Efficacy of the PDE4 inhibitor, Bay 19\u20108004, in a smoke\u2010induced model of pulmonary inflammation in the guinea pig","volume":"163","author":"Fitzgerald MF","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"50","key":"e_1_2_10_32_1","first-page":"663s","article-title":"Roflumilast but not methylprednisolone inhibited cigarette smoke\u2010induced pulmonary inflammation in guinea pigs","volume":"28","author":"Fitzgerald MF","year":"2006","journal-title":"Eur Respir J"},{"key":"e_1_2_10_33_1","unstructured":"Food and Drug Administration(2010).Daxas (roflumilast) tablets NDA 22\u2010522. Available at:http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Pulmonary\u2010AllergyDrugsAdvisoryCommittee\/UCM208711.pdf. (last accessed 19 October 2010)."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2006.06.016"},{"key":"e_1_2_10_35_1","unstructured":"FuruieH NakagawaS KawashimaM MurakamiM IrieS(2003).Suppressive effect of novel phosphodiesterase4 (PDE4) inhibitor ONO\u20106126 on TNF\u2010\u03b1 release was increased after repeated oral administration in healthy Japanese subjects. Presented at the13th Annual European Respiratory Society's Annual Congress Vienna Austria. September 27: Abstract 2557."},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(92)90160-K"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200504-041SR"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02640.x"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.297"},{"key":"e_1_2_10_40_1","volume-title":"Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (Updated 2009)","author":"Global Initiative for Chronic Obstructive Lung Disease","year":"2009"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1094-5539(03)00090-7"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S1761"},{"key":"e_1_2_10_43_1","first-page":"A5351","article-title":"Characterisation of a model that mimicks aspects of the hyper\u2010inflammatory response observed during an acute exacerbation of COPD","volume":"179","author":"Hardaker EL","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00857.x"},{"key":"e_1_2_10_45_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0022-3565(24)29537-9","article-title":"Anti\u2010inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro","volume":"297","author":"Hatzelmann A","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2010.03.011"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006291621"},{"key":"e_1_2_10_48_1","first-page":"436s","article-title":"\u2018Total PDE4 inhibitory activity\u2019: a concept for evaluating pharmacokinetic alterations of roflumilast and roflumilast N\u2010oxide in special populations and drug\u2010drug interactions","volume":"28","author":"Hermann R","year":"2006","journal-title":"Eur Respir J"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746050-00003"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007300950"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.31.19672"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.122041599"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.9.1489"},{"key":"e_1_2_10_55_1","first-page":"A4582","article-title":"In vivo characterisation of GSK256066, an exceptionally high affinity and selective inhibitor of PDE4 suitable for topical administration","volume":"179","author":"Knowles RG","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008321941"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.5414\/CPP47236"},{"issue":"54","key":"e_1_2_10_58_1","first-page":"Abstract P4593","article-title":"Roflumilast in coadministration with medications commonly prescribed for COPD: an overview of existing studies","volume":"36","author":"Lahu G","year":"2010","journal-title":"Eur Respir J"},{"key":"e_1_2_10_59_1","article-title":"Effect of steady\u2010state enoxacin on single\u2010dose pharmacokinetics of roflumilast and roflumilast N\u2010Oxide","author":"Lahu G","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.2165\/11536600-000000000-00000"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1996.tb00178.x"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.180"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)17708-3"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/01926230490431493"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.02007.x"},{"key":"e_1_2_10_66_1","first-page":"A4441","article-title":"Time course and reversibility of weight decrease with roflumilast, a phosphodiesterase 4 inhibitor","volume":"181","author":"Martinez FJ","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200411-1549OC"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2466-8-17"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0274com"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-6147(96)10035-3"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006297920"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02762.x"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03478.x"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02427280"},{"key":"e_1_2_10_75_1","unstructured":"Nycomed GmbH(2009).Data on file. Safety evaluation of roflumilast \u2013 mesenteric vasculitis. Nycomed GmbH (previously Altana Pharma AG) 358\/2008."},{"key":"e_1_2_10_76_1","unstructured":"Nycomed GmbH(2010a).Data on file Nycomed GmbH (previously Altana Pharma AG) 134\/2006."},{"key":"e_1_2_10_77_1","unstructured":"Nycomed GmbH(2010b).Data on file Nycomed GmbH (previously Byk Gulden Lomberg Chemische Fabrik GmbH) 213\/2000."},{"key":"e_1_2_10_78_1","first-page":"502","article-title":"Tetomilast","volume":"8","author":"O'Mahony S","year":"2005","journal-title":"Idrugs"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2009.01.015"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00194.x"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543770903313753"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.8.4820"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67100-0"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.2165\/0003495-200868002-00002"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-18"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746070-00006"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0215506"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2004.12.001"},{"key":"e_1_2_10_89_1","first-page":"15","article-title":"Cancer risk in patients with chronic obstructive pulmonary disease","volume":"1","author":"Schneider C","year":"2010","journal-title":"Pragmatic and Observational Research"},{"key":"e_1_2_10_90_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.029"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00185-5"},{"key":"e_1_2_10_92_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363230-00002"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.51.3.267"},{"key":"e_1_2_10_94_1","first-page":"A2224","article-title":"Does the impact of anti\u2010inflammatory compounds in acute smoking mouse models predict therapeutic efficacy in more chronic models","volume":"179","author":"Stevenson CS","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.46.7.512"},{"key":"e_1_2_10_96_1","first-page":"220s","article-title":"The pharmacological and safety profile of a novel selective phosphodiesterase\u20104(PDE4) inhibitor:\u2010 GRC\u2010 3886","volume":"24","author":"Vakkalanka SKVS","year":"2004","journal-title":"Eur Respir J"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.56.1.170"},{"key":"e_1_2_10_98_1","first-page":"A651","article-title":"Therapeutic effects of various PDE4 inhibitors on cigarette smoke\u2010induced pulmonary neutrophilia in mice","volume":"178","author":"Weidenbach A","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_10_99_1","unstructured":"WoutersEF TeichmannP BroseM FabbriL RabeK(2010a).Effect of roflumilast on glucose levels in patients with COPD and diabetes mellitus type 2. Presented at theEuropean Respiratory Society Annual Congress Barcelona Spain 18\u201022 September 2010: Poster 4002."},{"key":"e_1_2_10_100_1","first-page":"A4473","article-title":"Effects of roflumilast, a phosphodiesterase 4 inhibitor, on body composition in chronic obstructive pulmonary disease","volume":"181","author":"Wouters EFM","year":"2010","journal-title":"Am J Respir Crit Care Med"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2011.01218.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2011.01218.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T14:52:07Z","timestamp":1740840727000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2011.01218.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,6]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1111\/j.1476-5381.2011.01218.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01218.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,6]]},"assertion":[{"value":"2011-04-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}